Kornimate/medical-research-clean huggingface dataset:
effect of eswt on muscle architecture

Conditions: Tendinopathy

Summary: the aim of the research is to investigate the effect of ekstracorpereal shock wave treatment (eswt) on muscle strength, flexibility and architecture of the lower extremity tendinopathies when applied using the frequencies specified in the literature with min and max frequency frequencies. our hypothesis as researchers is eswt treatment has an effect on muscle strength, flexibility and muscle architecture.

the study will conduct in the physical therapy and radiology department in a private hospital. the clinical research ethics committee of gaziantep the univsersity approved ethical compliance of the study with the decision number go 2018-01. the participants will inform about the study and their write consent will obtain. demographic information including the name, age, height, body weight and occupation of the participants will obtain before the evaluation. all the measurements will perform before, soon after the 1st session and after the last session. outcome measures will be muscle strength, muscle flexibility, muscle architectures parameters.

Eligibility criteria:
inclusion criteria: lower extremity tendinopathy exclusion criteria: * patients who failed to show up to any treatment and measurement sessions, * patients who cannot tolerate treatment * having systemic inflammatory disease, * lower or upper motor lesion

Keywords: extracorporeal shockwave theraphy ultrasonography muscle strength
study to assess the efficacy and safety of raxone in lhon patients

Conditions: Leber's Hereditary Optic Neuropathy (LHON)

Summary: leros is an open-label interventional phase iv study, designed to further assess the efficacy and safety of raxone® in the long-term treatment of lhon patients.


Eligibility criteria:
inclusion criteria: 1. impaired visual acuity in affected eyes due to lhon 2. no explanation for visual loss besides lhon 3. age more or equal 12 years 4. onset of symptoms ≤5 years of baseline 5. confirmation of either g11778a, g3460a or t14484c lhon mtdna (for the intent-to treat (itt) population, not required for enrolment) 6. written informed consent obtained from the patient 7. ability and willingness to comply with study procedures and visits 8. women of childbearing potential (wcbp) who have a negative urine or serum pregnancy test at baseline visit and who are willing to use a highly effective contraceptive measure and maintain it until treatment discontinuation. exclusion criteria: 1. patient has provided natural history data to the case record survey (snt-crs-002) 2. any previous use of idebenone 3. any other cause of visual impairment (e.g. glaucoma, diabetic retinopathy, aids related visual impairment, cataract, macular degeneration, etc.) or any active ocular disorder (uveitis, infections, inflammatory retinal disease, thyroid eye disease, etc.) 4. known history of clinically significant elevations (greater than 3 times the upper limit of normal) of aspartate aminotransferase (ast), alanine transaminase (alt) or creatinine 5. patient has a condition or is in a situation which, in an investigator's opinion may put the patient at significant risk, may confound study results or may interfere significantly with the patient's participation in the study 6. participation in another clinical trial of any investigational drug within 3 months prior to baseline 7. hypersensitivity to the active substance or to any of the following excipients (as listed in section 6.1 of raxone smpc): lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, povidone k25, magnesium stearate, colloidal silica, macrogol 3350, poly(vinyl alcohol), talc, titanium dioxide, sunset yellow fcf (e110). 8. women who are pregnant or have a positive pregnancy test at baseline visit 9. women who are breastfeeding
an observational study (registry) assessing treatment outcomes and safety for children and adults who are prescribed norditropin® (human growth hormone)

Conditions: Growth Hormone Disorder; Pituitary Dwarfism; Hypopituitarism

Summary: this study is conducted in the united states of america (usa). the aim of this observational study is to collect data concerning the treatment outcomes and safety for children and adults who are prescribed norditropin®. specific objectives include: 1) developing models defining the relationship of norditropin dose to changes in insulin-like growth factor (igf-i) and treatment outcomes, accounting for independent factors such as age, gender and puberty and 2) determining the relative predictive values of peak growth hormone (gh) and igf-i levels and other factors before treatment to clinical outcomes.


Eligibility criteria:
inclusion criteria: * informed consent obtained * children or adult patients treated with norditropin® for an appropriate condition as prescribed by their physician exclusion criteria: * patients not being treated with norditropin® * patients who have discontinued treatment with norditropin® * known or suspected allergy to norditropin® or related products * contraindications for somatropin treatment consistent with the prescribing information for norditropin®
study to assess the impact of personalized coaching on the time period and quality of return to work after breast cancer

Conditions: Breast Cancer; Surgery

Summary: evaluate the impact of coaching sessions on the return to work rate (number of patients returning at work / total number of patients per arm) 6 months after inclusion in the study for breast cancer in professionnally active patients.


Eligibility criteria:
inclusion criteria: any patient active at the time of the diagnosis of breast cancer, treated consecutively at the institut curie during the study period, and whose first treatment will be surgery, will be offered participation in the study. 1. invasive non-metastatic breast cancer, treated first by surgery 2. age ≥ 18 and ≤ 60 years 3. active woman at the time of diagnosis 4. patient with internet access and email address 5. patient affiliated with a social security scheme, speaking and reading french 6. signature of informed consent exclusion criteria: 1. in situ breast cancer 2. history of breast cancer 3. metastatic breast cancer 4. inflammatory breast cancer 5. woman with a life expectancy \<6 months at the time of diagnosis (in relation to other serious chronic diseases) 6. persons deprived of liberty or under guardianship 7. impossibility to submit to the medical follow-up of the test for geographical, social or psychological reasons
safety study of multiple-vaccine to treat metastatic breast cancer

Conditions: Metastatic Breast Cancer

Summary: the purpose of this study is to evaluate the safety of hla-a\*2402 restricted epitope peptides cdca1，urlc10，kif20a，depdc1 and mphosph1 emulsified with montanide isa 51.

cdca1，urlc10，kif20a，depdc1 and mphosph1 have been identified as cancer specific molecules especially in breast cancer using genome-wide expression profile analysis by cdna microarray technique. we have determined the hla-a\*2402 restricted epitope peptides derived from these molecules and identified that these peptides significantly induce the effective tumor specific ctl response in vitro and vivo. according to these findings, in this trial, we evaluate the safety, immunological and clinical response of these peptides. patients will be vaccinated once a week until patients develop progressive disease or unacceptable toxicity. on each vaccination day, cdca1，urlc10，kif20a，depdc1 and mphosph1 peptides (0.5, 1 or 2mg of each peptide) mixed with montanide isa 51 will be administered by subcutaneous injection. repeated cycles of vaccine will be administered until patients develop progressive disease or unacceptable toxicity, whichever occurs first. in the phase i study, we evaluate the safety and tolerability of these peptides vaccine. also we evaluate the immunological and clinical response of this vaccine therapy.

Eligibility criteria:
inclusion criteria: * advanced or recurrent breast cancer * resistant against anthracycline-based and taxane-based chemotherapy or difficult to continue the chemotherapy due to intolerable side effect(s) * resistant against trastuzumab or difficult to continue it due to intolerable side effect(s) when her-2 is positive * ecog performance status 0-2 * life expectancy \> 3 months * hla-a\*2402 * laboratory values as follows * 2000/mm3\<wbc\<15000/mm3 * platelet count\>100000/mm3 * bilirubin \< 3.0mg/dl * asparate transaminase \< 150iu/l * alanine transaminase \< 150iu/l * creatinine \< 3.0mg/dl * able and willing to give valid written informed consent exclusion criteria: * pregnancy(woman of childbearing potential:refusal or inability to use effective means of contraception) * breastfeeding * active or uncontrolled infection * concurrent treatment with steroids or immunosuppressing agent * prior chemotherapy,radiation therapy, or immunotherapy within 4 weeks * decision of unsuitableness by principal investigator or physician-in-charge

Keywords: no number
fecal microbiota transplantation for decompensated cirrhosis

Conditions: Decompensated Cirrhosis; Fecal Microbiota Transplantation

Summary: imbalance of gut bacteria is suspected to play a key role driving the progression of cirrhosis and there is hope manipulation of these bacteria may be beneficial. this study will determine if fecal microbiota transplantation is an effective and safe treatment for decompensated cirrhosis.

two groups of inpatients with decompensated cirrhosis will be randomized using random sequence generator into experimental and control groups. two groups will given traditional treatments and experimental group will added treatment with fecal microbiota transplantation via endoscope and/or cenema.the liver function parameters, adverse events complication, systemic inflammatory markers, intestinal mucosa structure, permeability changes in the intestinal mucosal barrier, microbiota composition will be assessed and thereafter at 1 month and 3 months \& subjects will be clinically assessed for improvement or worsening.

Eligibility criteria:
inclusion criteria: 1. \>18 years of age 2. agreed to participate in this clinical study and signed informed consent, follow-up time greater than 3 months. 3. comply with the diagnostic criteria of decompensated liver cirrhosis, including liver function damage, portal hypertension clinical manifestations, laboratory and imaging studies. exclusion criteria: 1. ongoing bacterial infection requiring antibiotic treatment. 2. current or history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening (significant alcohol consumption is defined as more than 20 g/day in females and more than 30 g/day in males, on average). 3. consecutive months within 1 year prior to screening. 4. treatment with antibiotics or probiotics in the preceding 3 months. 5. inability to safely perform an gastrointestinal endoscopy. 6. no history of recent spontaneous bacterial peritonitis or gastrointestinal bleeding.(14 days). 7. human immunodeficiency virus (hiv) infection. 8. active, serious medical disease with likely life expectancy less than 5 years. 9. active substance abuse including inhaled or injection drugs in the year prior to screening. 10. pregnancy, planned pregnancy, potential for pregnancy and unwillingness to use effective birth control during the trial, breast feeding. 11. any other condition which, in the opinion of the investigator, would impede compliance or hinder completion of the study. 12. history of severe (anaphylactic) food allergy. 13. history of gastroparesis or altered gastric motility - 14. psychiatric disorder

Keywords: cirrhosis fecal microbiota transplantation intestinal flora intestinal mucosal barrier intestinal bacteria flora disturbance
baclofen as add-on to standard treatment of alcohol- dependent patients

Conditions: Alcohol Dependence

Summary: this is a study of baclofen as an add-on to standard treatment for alcohol-dependent patients.

double-blind, placebo-controlled, randomized trial comparing 50 mg/day of baclofen to placebo over 12 weeks, in addition to a low-intensity psychosocial intervention program, with 26-week and 52-week follow-up observations. the percentages of heavy drinking days and abstinent days were the primary outcome measures, and craving; distress and depression levels; self-efficacy; social support from family, friends and significant others; and health-related quality of life (hrql) were secondary outcomes. tolerability was also examined.

Eligibility criteria:
inclusion criteria: 1. icd-10 diagnosis of alcohol dependence (world health organization, 1993); 2. seeking treatment with the aim to stop alcohol consumption; 3. age ranging from 18 to 60 years; 4. last alcohol intake reported in the 24 h preceding observation; 5. presence of a referred family member; 6. written informed consent provision. exclusion criteria:. 1. serious hepatic, kidney, lung, neurological and cardiovascular, diseases); 2. suicide risk, acute psychosis, severe depression, organic brain syndromes; 3. dependence on psychoactive substances other than nicotine.

Keywords: baclofen alcohol baclofen as add-on to standard treatment of alcohol
self myofascial release in individuals with piriformis syndrome

Conditions: Piriformis Muscle Syndrome

Summary: piriformis syndrome is pain that extends from the hip to the knee, caused by the pressure of the piriformis muscle in the hip on the sciatic nerve. there is no valid protocol for the treatment of this syndrome. physiotherapists generally use hip strengthening exercises and modalities for pain. in this study, in addition to the classical treatment, we will give two different programs consisting of self-myofascial relaxation and stretching exercises to two different groups for 4 weeks as home exercise. we will question the level of pain that people felt in the hip before starting the exercises and at the 4th week after starting the exercises and measured the hip joint range of motion.

piriformis syndrome (ps) is a condition caused by compression of the sciatic nerve, causing pain, tingling, and numbness. although conservative treatment includes hip muscle strengthening and stretching, there is no proven treatment method in the literature. this study will be conducted to investigate the effect of stretching and myofascial release added to standard physiotherapy treatment in piriformis syndrome. this prospective, randomized controlled study will be planned to completed with 64 individuals between the ages of 20-40. participants will be randomized into the piriformis muscle stretch group (pim-s) and piriformis muscle self myofascial release group (pim-smr). both groups will be included in a home program of muscle strengthening exercises for 4 weeks. and groups will be subjected to perform stretching and self-myofascial relaxation exercises, respectively, in addition to the home exercise program. the primary outcome of the study is pain intensity, and the secondary outcome is determined as the range of motion (rom) of the hip.

Eligibility criteria:
inclusion criteria: * male and female participants * aged 20 to 40 years * presented leg or hip posterior compartment pain * diagnosed with chronic ps and without any other source of pain exclusion criteria: * any pathology or acute injury around the hip, sacroiliac joint, or lumbar spine; * limb length discrepancy, * recent buttock trauma, * deep gluteal syndrome, * extrapelvic compression of the sciatic nerve or sacral plexus ischiogluteal/ischiofemoral bursitis or impingement, upper hamstring tendinitis, * fibromyalgia, myofascial pain syndrome * pregnancy.

Keywords: piriformis syndrome pain hip range of motion sciatica
weight-bearing exercise for trans-tibial amputees

Conditions: Amputation

Summary: a simple weight-bearing exercise has been designed using off-the-shelves devices (nintendo wii balance board) and centre of pressure (cop) analysis software (python) for trans-tibial amputees receiving their first prosthesis. a pilot randomised control study will be conducted to check the progress with weight-bearing training using cop-based objective measures. additionally, gait and functional task performance will be assessed by means of clinical test. participants will be divided into 2 groups: test group (performing additional weight-bearing exercises) and control group (receiving only conventional training for fitting of initial prosthesis).

each patient meeting the inclusion criteria will be randomised to either the test group or the control group. the patients will perform ten training sessions with the initial prosthesis, each session lasting for about 30 minutes, within the period of two weeks. they will be assessed at baseline and after the training program.

Eligibility criteria:
inclusion criteria: * trans-tibial amputation, * fitted with first trans-tibial prosthesis, * independent mobility for 50m with or without assistive aid, * functional independence measure (fim) stairs locomotion scale ≥ 5, * ability to follow the instructions, mini mental state examination (mmse) \> 25, * no severe visual problems, ble to see computer screen, * willing to participate. exclusion criteria: * bilateral lower limb amputation or any other level of unilateral lower limb amputation, * not candidates for prosthetic fitting.

Keywords: trans-tibial prosthesis weight-bearing balance centre of pressure
effect of a single virtual reality exposure on depressive symptoms (veovita-vr)

Conditions: Depression

Summary: the trial aims to evaluate the effectiveness of a novel virtual reality (vr) intervention (veovita-vr) designed to expose people with at least moderate depressive symptoms to positive emotional stimuli and positive behavioral activation, thereby reducing depressive symptoms. therefore, 128 adults with at least moderate depressive symptoms (operationalized as a patient health questionnaire (phq-9) score ≥ 10) will be recruited and randomized into two groups: (1) a control group that may undergo depression treatment (care-as-usual, cau) and receive access to veovita-vr 5 weeks post-baseline (i.e., cau control group), or (2) to an intervention group that receives one veovita-vr session immediately after randomization and may also use cau. the primary endpoint is depressive symptom level as assessed with the patient health questionnaire (phq-9) 4 weeks post-baseline. additionally, depressive symptoms (phq-9) will be assessed 1 week post-baseline.


Eligibility criteria:
inclusion criteria: * age 18 years or older * phq-9 score ≥ 10 exclusion criteria: * apparent mental health problems other than depression (e.g., diagnosis of substance use disorder, psychotic disorder or bipolar disorder) * acute suicidality

Keywords: virtual reality depression
different positive pressure strategies in copd patients.

Conditions: Chronic Obstructive Pulmonary Disease

Summary: chronic obstructive pulmonary disease (copd) is characterized by a poorly reversible airway obstruction and consequent systemic manifestations. its high prevalence and high number of diagnosed patients has become a challenge for health services due to the costs of diagnosis and treatment of these patients. positive pressure and aerosol therapy are preferred therapies for the management of copd symptoms, but their effects when associated are poorly studied. the objective of this study is to compare the effects of different positive pressure strategies associated with aerosol therapy through pulmonary scintigraphy and electrical impedance tomography (eit) in patients with copd in the intercrise period. this is a randomized, crossover, blinded and allocated crossover type clinical trial in which patients with moderate to severe copd will be allocated to three intervention groups with different strategies for positive pressure associated with aerosol therapy: control group 1 nebulization), group 2 nebulization with epap valve and group 3 nebulization with niv bi-level pressure mode. the radioaerosol deposition pattern will be evaluated through pulmonary scintigraphy and regional pulmonary ventilation through eit.


Eligibility criteria:
inclusion criteria: * patients with stage ii (moderate) and iii (severe) copd according to the guidelines of the global initiative for chronic obstructive lung disease (gold) exclusion criteria: * unable to understand or perform procedures that present rheumatic or orthopedic diseases or deformities / abnormalities in the spine that compromise the mechanics of the respiratory system; respiratory comorbidities such as asthma, bronchiectasis and sequela of tuberculosis, cardiovascular and neurological comorbidities; hemodynamic instability defined as heart rate greater than 150 bpm, or systolic pressure less than 90 mmhg; hypertension (blood pressure\> 149/89 mmhg) or hypotension (blood pressure \<90/60 mmhg) at the time of collection; pregnancy or suspected pregnancy; and any contraindications for the use of pep.

Keywords: aerosol therapy positive pressure electrical impedance tomography pulmonary scintigraphy
the effect of semi fowler 30' right lateral on cardiac output in acute heart failure

Conditions: Cardiac Output, High; Heart Failure; Pulmonary Edema With Heart Failure; Dyspnea; Cardiac; Arrythmia

Summary: heart failure is a special clinical syndrome such as difficulty breathing, fatigue, and swollen legs characterized by increased jvp, crackle lung sounds, and peripheral edema caused by heart disorders both structural and/or functional, resulting in decreased cardiac output and increased intracardiac pressure at rest and activity. body positioning has been shown to affect stroke volume and parasympathetic modulating activity. the right lateral 30" semifowler position is a very safe position in heart failure patients admitted to the icu. although body positioning can affect stroke volume, and parasympathetic modulation, it is not yet clear what effect it has on cardiac output


Eligibility criteria:
inclusion criteria: * the patient was diagnosed with acute decompensated heart failure, * fully conscious, * not intubated, * \>18 years old, * had no mobility problems, * palpable radial artery pulsation, * was not under the influence of anti-hypotensive drugs, * willing to be a respondent, * lvef \<50%. exclusion criteria: * pulmonary edema, * severe valve disease comorbidities, * receiving high doses of anti-hypotensive treatment, * heart failure readmission in the last 3 months, * finger edema, * use of mechanical circulatory support, * irregular rhythms, * artificial pacemaker attached, * obesity * peripheral perfusion disorders * cardiogenic shock

Keywords: cardiac output heart failure body positioning right lateral body position semifowler